Aurobindo Gets USFDA Nod to Launch Generic Xarelto 2.5mg in $447M US Market

Published • 13 April 2025 at 10:24 AM

Aurobindo receives USFDA approval for generic anticoagulant Rivaroxaban 2.5mg
Aurobindo Pharma gets USFDA nod to launch generic Xarelto 2.5mg targeting $447M US market.
CNBCTV 18

Aurobindo Pharma has received final approval from the USFDA to manufacture and market Rivaroxaban Tablets USP, 2.5mg — the generic version of Janssen’s blockbuster drug Xarelto. The Hyderabad-based pharmaceutical company plans to launch the product in Q1 of FY2025-26. The US market for this strength alone is estimated at $447 million for the 12 months ending February 2025, according to IQVIA. In addition, Aurobindo has secured tentative USFDA approvals for Rivaroxaban in 10mg, 15mg, and 20mg strengths, targeting a broader $8.5 billion US market for all doses. Rivaroxaban is an anticoagulant used to reduce stroke and embolism risks in patients with nonvalvular atrial fibrillation, and for treating or preventing deep vein thrombosis (DVT) and pulmonary embolism (PE). This milestone brings Aurobindo’s total USFDA-approved ANDAs to 540, including 521 final and 19 tentative approvals. With operations in over 150 countries, Aurobindo continues to expand its diverse portfolio across key therapeutic areas such as CNS, cardiovascular, anti-retrovirals, gastroenterology, anti-diabetics, and antibiotics.

Key Highlights
  • USFDA Approval: Aurobindo Pharma received final USFDA approval to manufacture and market Rivaroxaban Tablets USP, 2.5mg — the generic version of Xarelto.
  • Product Launch: The company plans to launch the product in Q1 of FY2025-26.
  • Market Value: The US market for the 2.5mg strength is valued at approximately $447 million (as of February 2025, IQVIA data).
  • Tentative Approvals: Aurobindo also secured tentative USFDA approvals for 10mg, 15mg, and 20mg Rivaroxaban tablets.
  • Total Market Opportunity: The full US market for all Rivaroxaban strengths is estimated at $8.5 billion.
  • Therapeutic Use: Rivaroxaban is an anticoagulant used to prevent stroke, DVT, and pulmonary embolism.
  • ANDA Milestone: Aurobindo now has 540 ANDA approvals from the USFDA — 521 final and 19 tentative.
  • Global Reach: The company operates in over 150 countries.
  • Therapeutic Coverage: Aurobindo’s portfolio includes CNS, cardiovascular, anti-retrovirals, gastroenterology, anti-diabetics, and antibiotics.
  • Strategic Growth: This approval strengthens Aurobindo’s presence in the high-value US generics market.

Latest News

BPSL faces liquidation after ₹19,700 crore bid by JSW Steel deemed illegal by court

SC Orders Liquidation of Bhushan Power, Rejects JSW Steel Plan as Illegal

Published • 2 May 2025 at 7:26 AM
Reliance Power inks ₹10,000 crore deal for 930 MW solar and 1,860 MWh BESS with SECI

Reliance NU Suntech Signs ₹10,000 Crore PPA for 930 MW Solar Power

Published • 2 May 2025 at 5:44 AM
Brunson’s clutch buzzer-beater seals series and sparks iconic “double bang” from Mike Breen.

Jalen Brunson's Clutch Shot Sends Knicks to Victory; Iconic "Double Bang!"

Published • 2 May 2025 at 4:57 AM
Amazon exceeds Q1 earnings estimates but lowers Q2 guidance, citing tariffs and trade concerns.

Amazon Q1 Earnings Beat, But Soft Q2 Guidance Amid Tariff Concerns

Published • 1 May 2025 at 10:52 PM
Reddit shares soar 20% after Q1 earnings beat, revenue hits $392M with 108M daily users.

Reddit Crushes Q1 Expectations: Shares Soar 20% on Earnings

Published • 1 May 2025 at 10:37 PM
Ford April sales increase 16% with strong truck demand, but EV sales decline 40%.

Ford U.S. Sales Rise 16% in April Despite 40% EV Sales Drop

Published • 1 May 2025 at 3:26 PM
GM lowers 2025 profit forecast amid $5B tariff impact; ramps up U.S. production efforts.

GM Cuts 2025 Profit Outlook by $4B-$5B Due to US Tariffs

Published • 1 May 2025 at 3:03 PM
Barclays posts £2.7B Q1 profit, boosted by 21% rise in fixed income trading revenue.

Barclays Q1 Profit Soars 19% to £2.7B, Beats Expectations

Published • 30 April 2025 at 7:23 AM
IndusInd Bank stock gains 3% as Deputy CEO Arun Khurana resigns citing trading issues.

IndusInd Bank Deputy CEO Resigns on Loss; Stock Shows Resilience

Published • 29 April 2025 at 4:51 AM
IBM commits $150 billion for U.S. manufacturing push, focusing on quantum computing growth.

IBM to Invest $150B in US, Boost Quantum & Mainframe Production

Published • 28 April 2025 at 4:27 PM
Wells Fargo advances toward lifting $1.95 trillion asset cap after consent order termination.

Wells Fargo Clears Another Hurdle, Nears End of Consent Orders

Published • 28 April 2025 at 2:05 PM
Adani Ports to acquire North Queensland Export Terminal for $2.54B in global expansion move

Adani Ports to Acquire Australian Export Terminal for $2.54 Billion

Published • 18 April 2025 at 12:54 PM